enGene (ENGN) Competitors

$1.73 +0.12 (+7.45%)

Closing price 04:00 PM Eastern

Extended Trading

$1.68 -0.05 (-2.66%)

As of 07:11 PM Eastern

ENGN vs. DTSS, OVID, IRD, SNDL, and PBYI

Should you buy enGene stock or one of its competitors? MarketBeat compares enGene with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with enGene include Datasea (DTSS), Ovid Therapeutics (OVID), Opus Genetics (IRD), SNDL (SNDL), and Puma Biotechnology (PBYI).

How does enGene compare to Datasea?

Datasea (NASDAQ:DTSS) and enGene (NASDAQ:ENGN) are related small-cap companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and valuation.

enGene has a net margin of 0.00% compared to Datasea's net margin of -4.80%. enGene's return on equity of -55.83% beat Datasea's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Datasea	-4.80%	-88.98%	-37.33%
enGene	N/A	-55.83%	-45.74%

Datasea has a beta of 0.8, suggesting that its stock price is 20% less volatile than the broader market. Comparatively, enGene has a beta of -0.02, suggesting that its stock price is 102% less volatile than the broader market.

In the previous week, enGene had 11 more articles in the media than Datasea. MarketBeat recorded 11 mentions for enGene and 0 mentions for Datasea. enGene's average media sentiment score of 0.24 beat Datasea's score of 0.00 indicating that enGene is being referred to more favorably in the news media.

Company	Overall Sentiment
Datasea	Neutral
enGene	Neutral

Datasea has higher revenue and earnings than enGene. Datasea is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Datasea	$71.62M	0.12	-$5.09M	-$0.32	N/A
enGene	N/A	N/A	-$117.30M	-$2.25	N/A

enGene has a consensus target price of $12.68, indicating a potential upside of 633.05%. Given enGene's stronger consensus rating and higher probable upside, analysts clearly believe enGene is more favorable than Datasea.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Datasea	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
enGene	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21

82.1% of Datasea shares are owned by institutional investors. Comparatively, 64.2% of enGene shares are owned by institutional investors. 50.7% of Datasea shares are owned by insiders. Comparatively, 10.5% of enGene shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

enGene beats Datasea on 8 of the 15 factors compared between the two stocks.

How does enGene compare to Ovid Therapeutics?

enGene (NASDAQ:ENGN) and Ovid Therapeutics (NASDAQ:OVID) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, risk, earnings, analyst recommendations and media sentiment.

enGene has a net margin of 0.00% compared to Ovid Therapeutics' net margin of -240.11%. Ovid Therapeutics' return on equity of -22.51% beat enGene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
enGene	N/A	-55.83%	-45.74%
Ovid Therapeutics	-240.11%	-22.51%	-18.67%

64.2% of enGene shares are held by institutional investors. Comparatively, 72.2% of Ovid Therapeutics shares are held by institutional investors. 10.5% of enGene shares are held by insiders. Comparatively, 13.1% of Ovid Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

enGene presently has a consensus price target of $12.68, indicating a potential upside of 633.05%. Ovid Therapeutics has a consensus price target of $5.13, indicating a potential upside of 110.04%. Given enGene's higher probable upside, equities analysts clearly believe enGene is more favorable than Ovid Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
enGene	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21
Ovid Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

In the previous week, enGene had 4 more articles in the media than Ovid Therapeutics. MarketBeat recorded 11 mentions for enGene and 7 mentions for Ovid Therapeutics. enGene's average media sentiment score of 0.24 beat Ovid Therapeutics' score of -0.56 indicating that enGene is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
enGene	2 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral
Ovid Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative

Ovid Therapeutics has higher revenue and earnings than enGene. Ovid Therapeutics is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
enGene	N/A	N/A	-$117.30M	-$2.25	N/A
Ovid Therapeutics	$7.25M	44.38	-$17.41M	-$0.29	N/A

enGene has a beta of -0.02, meaning that its share price is 102% less volatile than the broader market. Comparatively, Ovid Therapeutics has a beta of 0.18, meaning that its share price is 82% less volatile than the broader market.

Summary

Ovid Therapeutics beats enGene on 11 of the 16 factors compared between the two stocks.

How does enGene compare to Opus Genetics?

Opus Genetics (NASDAQ:IRD) and enGene (NASDAQ:ENGN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, media sentiment, risk, profitability, analyst recommendations and valuation.

In the previous week, Opus Genetics had 4 more articles in the media than enGene. MarketBeat recorded 15 mentions for Opus Genetics and 11 mentions for enGene. enGene's average media sentiment score of 0.24 beat Opus Genetics' score of -0.01 indicating that enGene is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Opus Genetics	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
enGene	2 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral

Opus Genetics has a beta of 0.62, suggesting that its share price is 38% less volatile than the broader market. Comparatively, enGene has a beta of -0.02, suggesting that its share price is 102% less volatile than the broader market.

Opus Genetics currently has a consensus price target of $10.18, indicating a potential upside of 137.34%. enGene has a consensus price target of $12.68, indicating a potential upside of 633.05%. Given enGene's higher possible upside, analysts clearly believe enGene is more favorable than Opus Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Opus Genetics	2 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.80
enGene	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21

Opus Genetics has higher revenue and earnings than enGene. Opus Genetics is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Opus Genetics	$14.20M	24.59	-$49.59M	-$1.33	N/A
enGene	N/A	N/A	-$117.30M	-$2.25	N/A

enGene has a net margin of 0.00% compared to Opus Genetics' net margin of -892.36%. enGene's return on equity of -55.83% beat Opus Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Opus Genetics	-892.36%	-338.88%	-191.21%
enGene	N/A	-55.83%	-45.74%

15.0% of Opus Genetics shares are owned by institutional investors. Comparatively, 64.2% of enGene shares are owned by institutional investors. 11.7% of Opus Genetics shares are owned by company insiders. Comparatively, 10.5% of enGene shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Opus Genetics beats enGene on 9 of the 16 factors compared between the two stocks.

How does enGene compare to SNDL?

SNDL (NASDAQ:SNDL) and enGene (NASDAQ:ENGN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends, profitability and media sentiment.

64.2% of enGene shares are held by institutional investors. 10.5% of enGene shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, enGene had 11 more articles in the media than SNDL. MarketBeat recorded 11 mentions for enGene and 0 mentions for SNDL. enGene's average media sentiment score of 0.24 beat SNDL's score of 0.00 indicating that enGene is being referred to more favorably in the news media.

Company	Overall Sentiment
SNDL	Neutral
enGene	Neutral

SNDL currently has a consensus target price of $5.00, indicating a potential upside of 240.14%. enGene has a consensus target price of $12.68, indicating a potential upside of 633.05%. Given enGene's stronger consensus rating and higher probable upside, analysts plainly believe enGene is more favorable than SNDL.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SNDL	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
enGene	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21

SNDL has a beta of 0.88, meaning that its share price is 12% less volatile than the broader market. Comparatively, enGene has a beta of -0.02, meaning that its share price is 102% less volatile than the broader market.

SNDL has higher revenue and earnings than enGene. SNDL is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SNDL	$937.39M	0.40	-$11.29M	-$0.03	N/A
enGene	N/A	N/A	-$117.30M	-$2.25	N/A

enGene has a net margin of 0.00% compared to SNDL's net margin of -1.19%. SNDL's return on equity of -1.02% beat enGene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SNDL	-1.19%	-1.02%	-0.85%
enGene	N/A	-55.83%	-45.74%

Summary

enGene beats SNDL on 9 of the 15 factors compared between the two stocks.

How does enGene compare to Puma Biotechnology?

enGene (NASDAQ:ENGN) and Puma Biotechnology (NASDAQ:PBYI) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, valuation, dividends, earnings and analyst recommendations.

enGene has a beta of -0.02, suggesting that its stock price is 102% less volatile than the broader market. Comparatively, Puma Biotechnology has a beta of 1.24, suggesting that its stock price is 24% more volatile than the broader market.

enGene currently has a consensus price target of $12.68, suggesting a potential upside of 633.05%. Given enGene's stronger consensus rating and higher possible upside, analysts plainly believe enGene is more favorable than Puma Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
enGene	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21
Puma Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, enGene had 9 more articles in the media than Puma Biotechnology. MarketBeat recorded 11 mentions for enGene and 2 mentions for Puma Biotechnology. Puma Biotechnology's average media sentiment score of 0.33 beat enGene's score of 0.24 indicating that Puma Biotechnology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
enGene	2 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral
Puma Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Puma Biotechnology has higher revenue and earnings than enGene. enGene is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
enGene	N/A	N/A	-$117.30M	-$2.25	N/A
Puma Biotechnology	$228.40M	1.57	$31.11M	$0.48	14.69

Puma Biotechnology has a net margin of 10.69% compared to enGene's net margin of 0.00%. Puma Biotechnology's return on equity of 20.30% beat enGene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
enGene	N/A	-55.83%	-45.74%
Puma Biotechnology	10.69%	20.30%	12.05%

64.2% of enGene shares are held by institutional investors. Comparatively, 61.3% of Puma Biotechnology shares are held by institutional investors. 10.5% of enGene shares are held by company insiders. Comparatively, 22.2% of Puma Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Puma Biotechnology beats enGene on 10 of the 15 factors compared between the two stocks.

Get enGene News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ENGN vs. The Competition

Export

Metric	enGene	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$115.89M	$3.36B	$6.34B	$12.29B
Dividend Yield	N/A	2.32%	2.80%	5.36%
P/E Ratio	-0.77	19.01	20.94	25.47
Price / Sales	N/A	278.84	521.15	73.36
Price / Cash	N/A	125.35	43.18	55.00
Price / Book	0.67	6.90	9.98	7.00
Net Income	-$117.30M	$24.23M	$3.55B	$335.16M
7 Day Performance	-4.42%	0.59%	0.42%	-0.29%
1 Month Performance	-79.67%	-0.61%	0.00%	1.15%
1 Year Performance	-57.18%	63.26%	34.99%	34.79%

enGene Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ENGN enGene	3.6438 of 5 stars	$1.73 +7.5%	$12.68 +633.1%	-61.7%	$115.89M	N/A	N/A	31
DTSS Datasea	0.6442 of 5 stars	$0.83 -1.8%	N/A	-64.8%	$8.72M	$71.62M	N/A	120
OVID Ovid Therapeutics	2.4779 of 5 stars	$2.87 +2.9%	$4.63 +61.1%	+724.7%	$378.50M	$7.25M	N/A	60	Positive News
IRD Opus Genetics	3.2134 of 5 stars	$5.18 +1.2%	$10.30 +98.8%	+346.7%	$369.85M	$14.20M	N/A	14	Analyst Forecast Insider Trade Analyst Revision
SNDL SNDL	2.8243 of 5 stars	$1.41 -1.4%	$5.00 +254.6%	+8.3%	$362.93M	$677.32M	N/A	2,751

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ENGN) was last updated on 5/21/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

enGene (ENGN) Competitors

ENGN vs. DTSS, OVID, IRD, SNDL, and PBYI

How does enGene compare to Datasea?

Summary

How does enGene compare to Ovid Therapeutics?

Summary

How does enGene compare to Opus Genetics?

Summary

How does enGene compare to SNDL?

Summary

How does enGene compare to Puma Biotechnology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENGN vs. The Competition

enGene Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

enGene (ENGN) Competitors

ENGN vs. DTSS, OVID, IRD, SNDL, and PBYI

How does enGene compare to Datasea?

Is DTSS or ENGN more profitable?

Which has more risk and volatility, DTSS or ENGN?

Does the media refer more to DTSS or ENGN?

Which has higher valuation and earnings, DTSS or ENGN?

Do analysts rate DTSS or ENGN?

Do institutionals and insiders believe in DTSS or ENGN?

Summary

How does enGene compare to Ovid Therapeutics?

Is ENGN or OVID more profitable?

Do institutionals and insiders believe in ENGN or OVID?

Do analysts recommend ENGN or OVID?

Does the media prefer ENGN or OVID?

Which has preferable valuation & earnings, ENGN or OVID?

Which has more volatility & risk, ENGN or OVID?

Summary

How does enGene compare to Opus Genetics?

Does the media favor IRD or ENGN?

Which has more risk and volatility, IRD or ENGN?

Do analysts prefer IRD or ENGN?

Which has higher valuation & earnings, IRD or ENGN?

Is IRD or ENGN more profitable?

Do insiders & institutionals have more ownership in IRD or ENGN?

Summary

How does enGene compare to SNDL?

Do institutionals & insiders believe in SNDL or ENGN?

Does the media favor SNDL or ENGN?

Do analysts recommend SNDL or ENGN?

Which has more volatility and risk, SNDL or ENGN?

Which has stronger valuation & earnings, SNDL or ENGN?

Is SNDL or ENGN more profitable?

Summary

How does enGene compare to Puma Biotechnology?

Which has more risk and volatility, ENGN or PBYI?

Do analysts prefer ENGN or PBYI?

Does the media prefer ENGN or PBYI?

Which has better valuation & earnings, ENGN or PBYI?

Is ENGN or PBYI more profitable?

Do insiders & institutionals have more ownership in ENGN or PBYI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENGN vs. The Competition

enGene Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools